ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03066661
Expanded Access Status : Temporarily not available
First Posted : February 28, 2017
Last Update Posted : May 15, 2018
Sponsor:
Information provided by (Responsible Party):
Ignyta, Inc.

Brief Summary:
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Condition or disease Intervention/treatment
Cancers With NTRK, ROS1, or ALK Gene Fusions Drug: Entrectinib

Study Type : Expanded Access
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Entrectinib
    Open-label expanded access, capsules
    Other Name: RXDX-101

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
  • Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
  • Willing and able to provide written, signed informed consent
  • Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion Criteria:

  • Currently enrolled in an ongoing clinical study with any other investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066661


Locations
United States, California
1-844-Startrk (782-7875)
San Diego, California, United States, 92121
Sponsors and Collaborators
Ignyta, Inc.

Responsible Party: Ignyta, Inc.
ClinicalTrials.gov Identifier: NCT03066661     History of Changes
Other Study ID Numbers: Entrectinib (RXDX-101) - EAP
First Posted: February 28, 2017    Key Record Dates
Last Update Posted: May 15, 2018
Last Verified: May 2018